2002
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer 2002, 95: 340-353. PMID: 12124835, DOI: 10.1002/cncr.10629.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntimetabolites, AntineoplasticAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBiological TherapyCarcinoma, Non-Small-Cell LungCombined Modality TherapyDeoxycytidineDisease ProgressionFemaleGemcitabineHumansLung NeoplasmsMaleMiddle AgedSurvival RateVinblastineVinorelbineConceptsNonsmall cell lung carcinomaYear survival rateAdvanced nonsmall cell lung carcinomaThird-line therapyPhase II trialMedian survival timeCell lung carcinomaGrade 3Survival rateSignificant myelosuppressionStable diseaseII trialLung carcinomaSurvival timeStage IV nonsmall cell lung carcinomaDay 1Day 15Formal phase II trialCurrent phase II trialDose of vinorelbineGemcitabine/vinorelbineGrade 3 granulocytopeniaMedian performance statusMinimal grade 3Prior chemotherapy regimens
1999
Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
Poplin E, Roberts J, Tombs M, Grant S, Rubin E. Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study. Investigational New Drugs 1999, 17: 57-61. PMID: 10555123, DOI: 10.1023/a:1006239200772.Peer-Reviewed Original ResearchConceptsCombination of leucovorinECOG performance status 0Refractory solid tumor malignanciesMedian performance statusPerformance status 0Phase I trialSolid tumor malignanciesTreatment of lungPrior chemotherapyPrior therapyStatus 0Performance statusStarting doseHepatic reserveI trialPartial responseMedian ageGemcitabine administrationDisease progressionDrug sequenceBreast cancerChemotherapy agentsMedian numberLeucovorinDay 28
1998
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. PMID: 9573002, DOI: 10.1182/blood.v91.10.3662.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisAntineoplastic Agents, AlkylatingCohort StudiesCombined Modality TherapyErythrocyte TransfusionFemaleHematopoietic Stem Cell TransplantationHumansKidneyLife TablesLiverMaleMelphalanMiddle AgedMyocardiumNervous SystemParaproteinsPlatelet TransfusionPrognosisRecurrenceSeverity of Illness IndexSurvival AnalysisTransplantation ConditioningTreatment OutcomeConceptsClonal plasma cell disorderPlasma cell disordersAL amyloidosisCell disordersPerformance statusComplete responseOrgan involvementAutologous stem cell transplantationBlood stem cell supportSignificant negative prognostic factorOrgan systemsDose-intensive melphalanDose-intensive therapyMedian performance statusPredominant cardiac involvementPerformance status 1Year of diagnosisGranulocyte-colony stimulating factorNegative prognostic factorStem cell supportBiopsy-proven amyloidosisProgressive organ failureStem cell transplantationMajor organ systemsPrior therapyDose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. DOI: 10.1182/blood.v91.10.3662.3662_3662_3670.Peer-Reviewed Original ResearchClonal plasma cell disorderPlasma cell disordersAL amyloidosisCell disordersPerformance statusComplete responseOrgan involvementAutologous stem cell transplantationBlood stem cell supportSignificant negative prognostic factorOrgan systemsDose-intensive melphalanDose-intensive therapyMedian performance statusPredominant cardiac involvementPerformance status 1Year of diagnosisGranulocyte-colony stimulating factorNegative prognostic factorStem cell supportBiopsy-proven amyloidosisProgressive organ failureStem cell transplantationMajor organ systemsPrior therapy
1997
RADICAL CYSTECTOMY IN THE OCTOGENARIAN
Stroumbakis N, Herr H, Cookson M, Fair W. RADICAL CYSTECTOMY IN THE OCTOGENARIAN. Journal Of Urology 1997, 158: 2113-2117. PMID: 9366325, DOI: 10.1016/s0022-5347(01)68171-0.Peer-Reviewed Original ResearchConceptsInvasive bladder cancerBladder cancerMedian performance statusOutcome of cystectomyUse of cystectomyMedian hospital stayPatients 80 yearsMore medical problemsMedian survival timePatients 78Surgery 66Acceptable morbidityHospital stayOperative mortalityComplication ratePerformance statusSurgical complicationsMedian ageRadical cystectomySurgical reasonsUrinary diversionMedical illnessIntensive careFunctional statusQuality survival
1996
Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five Patients
Comenzo R, Vosburgh E, Simms R, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller D, Wright D, Falk R, Skinner M. Dose-Intensive Melphalan With Blood Stem Cell Support for the Treatment of AL Amyloidosis: One-Year Follow-up in Five Patients. Blood 1996, 88: 2801-2806. PMID: 8839879, DOI: 10.1182/blood.v88.7.2801.bloodjournal8872801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisCardiomyopathiesFeasibility StudiesFemaleFollow-Up StudiesGastrointestinal DiseasesGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell TransplantationHepatomegalyHumansKarnofsky Performance StatusMaleMelphalanMiddle AgedNephrotic SyndromeNeutropeniaPeripheral Nervous System DiseasesPrednisoneRemission InductionTreatment OutcomeConceptsBlood stem cell supportStem cell supportPlasma cell dyscrasiaDose-intensive melphalanPerformance statusAL amyloidosisCell dyscrasiaCell supportClinical remissionIntravenous melphalanBone marrow biopsy specimensDose-intensive chemotherapyFibrillar amyloid proteinsImproved performance statusMedian performance statusSurvival of patientsTime of diagnosisReversal of symptomsBlood stem cellsClonal plasma cellsOne-year followOrgan-specific diseasesMarrow biopsy specimensForm of treatmentDaily proteinuria
1989
Low-Dose Continuous Infusion 5-Fluorouracil and Cisplatin
LoRusso P, Pazdur R, Redman B, Kinzie J, Vaitkevicius V. Low-Dose Continuous Infusion 5-Fluorouracil and Cisplatin. American Journal Of Clinical Oncology 1989, 12: 486-490. PMID: 2686394, DOI: 10.1097/00000421-198912000-00005.Peer-Reviewed Original ResearchConceptsContinuous infusionLow-dose continuous infusionMedian performance statusHand-foot syndromeSubclavian vein thrombosisDose continuous infusionMeasurable diseaseMedian durationMedian survivalPartial responsePerformance statusVein thrombosisComplete responseMedian ageGastric ulcerationPatientsSingle agentAntineoplastic activityCisplatinMonthsRest periodInfusionTrialsSurvivalToxicity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply